WO2010135493A3 - Agents d'imagerie utilisés pour la maladie d'alzheimer - Google Patents

Agents d'imagerie utilisés pour la maladie d'alzheimer Download PDF

Info

Publication number
WO2010135493A3
WO2010135493A3 PCT/US2010/035517 US2010035517W WO2010135493A3 WO 2010135493 A3 WO2010135493 A3 WO 2010135493A3 US 2010035517 W US2010035517 W US 2010035517W WO 2010135493 A3 WO2010135493 A3 WO 2010135493A3
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
alzheimer
imaging agents
deposits
disease imaging
Prior art date
Application number
PCT/US2010/035517
Other languages
English (en)
Other versions
WO2010135493A2 (fr
Inventor
Mark M. Goodman
Fanxing Zeng
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2010135493A2 publication Critical patent/WO2010135493A2/fr
Publication of WO2010135493A3 publication Critical patent/WO2010135493A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne des composés et des méthodes d'imagerie de dépôts amyloïdes utilisant des composés marqués par radioactivité. Cette invention concerne également une méthode d'inhibition de l'agrégation de protéines amyloïdes formant des plaques ou dépôts amyloïdes, une méthode de détermination de la capacité d'un composé thérapeutique à inhiber l'agrégation des protéines amyloïdes, et une méthode permettant d'administrer un agent thérapeutique à ces dépôts amyloïdes.
PCT/US2010/035517 2009-05-20 2010-05-20 Agents d'imagerie utilisés pour la maladie d'alzheimer WO2010135493A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17983609P 2009-05-20 2009-05-20
US61/179,836 2009-05-20

Publications (2)

Publication Number Publication Date
WO2010135493A2 WO2010135493A2 (fr) 2010-11-25
WO2010135493A3 true WO2010135493A3 (fr) 2011-04-21

Family

ID=43126762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/035517 WO2010135493A2 (fr) 2009-05-20 2010-05-20 Agents d'imagerie utilisés pour la maladie d'alzheimer

Country Status (1)

Country Link
WO (1) WO2010135493A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107400078A (zh) * 2017-07-03 2017-11-28 华中科技大学鄂州工业技术研究院 带永久电荷琥珀酯类糖标记物的制备方法及应用
CN107501123B (zh) * 2017-07-03 2020-04-28 华中科技大学鄂州工业技术研究院 带永久电荷肼类糖标记物的制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105266A1 (en) * 2007-04-19 2009-04-23 Ralf Glatthar Organic compounds
US20090118275A1 (en) * 2007-09-24 2009-05-07 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105266A1 (en) * 2007-04-19 2009-04-23 Ralf Glatthar Organic compounds
US20090118275A1 (en) * 2007-09-24 2009-05-07 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, Y. R. ET AL.: "Synthesis of thia(oxa)zolopyridines and their inhibitory activities for beta-amyloid fibrillization", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 29, no. 12, 2008, pages 2331 - 2336, XP008150933, DOI: doi:10.5012/bkcs.2008.29.12.2331 *

Also Published As

Publication number Publication date
WO2010135493A2 (fr) 2010-11-25

Similar Documents

Publication Publication Date Title
WO2007033080A3 (fr) Agents d'imagerie pour la maladie d'alzheimer
NO2018030I1 (no) Florbetapir (18F)
MX2007007380A (es) Derivados de estilbeno y su uso para estudios de union y por imagenes de placas amiloides.
EP2382176A4 (fr) Utilisation d'analogues de curcumine contenant de l'azote pour le traitement de la maladie d'alzheimer
WO2008073350A3 (fr) Dérivés d'acétylène et leur utilisation pour lier et imager des plaques amyloïdes
WO2008003943A3 (fr) Inhibition d'agrégation d'alpha-synucléine
WO2006078384A3 (fr) Derives de stilbene et leur utilisation pour fixer et imager des plaques amyloides
WO2011045415A3 (fr) Nouveaux agents d'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératives, notamment la maladie d'alzheimer et les maladies dérivées
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
EP1855679A4 (fr) Inhibiteurs de la beta-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
ZA200809857B (en) Terphenyl derivatives for treatment of alzheimer's disease
WO2007092861A3 (fr) Inhibition preferentielle de la preseniline-i
MA35347B1 (fr) Procedes therapeuiques
EP2398789A4 (fr) Inhibiteurs de bêta-sécrétase de type spiropyrrolidine pour le traitement de la maladie d'alzheimer
WO2008026040A3 (fr) Produits radiopharmaceutiques à base de peptides étiquetés ga
HK1110211A1 (fr)
WO2006136454A3 (fr) Utilisation d'inhibiteurs de n-methyltransferases dans la therapie de la maladie de parkinson
WO2010135493A3 (fr) Agents d'imagerie utilisés pour la maladie d'alzheimer
EP2241885A4 (fr) Agent et procédé pour le diagnostic de l'apparition de la maladie d'alzheimer ou de la tendance à développer la maladie d'alzheimer
WO2008057599A3 (fr) Procédés de traitement de troubles associés à l'abeta et compositions
UA91996C2 (ru) Производные стильбена и их применение для связывания и визуализации амилоидных бляшек
EP2305629A4 (fr) Agent thérapeutique pour la maladie d'alzheimer
IL220163A0 (en) Methods for the preparation of indazole-3-carboxyclic acid and n-(s)-1- azabicyclo[2.2.2] oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
EP2099476A4 (fr) Procédés de traitement de maladie d'alzheimer
IL208127A0 (en) Ptph1 inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10778364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10778364

Country of ref document: EP

Kind code of ref document: A2